Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia
Authors:
- Yulia DavydovaYDYulia Davydova
- Irina GaltsevaIGIrina Galtseva
- Nikolay KapranovNKNikolay Kapranov
- Ksenia NikiforovaKNKsenia Nikiforova
- Olga AleshinaOAOlga Aleshina
- Yulia ChabaevaYCYulia Chabaeva
- Galina IsinovaGIGalina Isinova
- Ekaterina KotovaEKEkaterina Kotova
- Andrey SokolovASAndrey Sokolov
- Vera TroitskayaVTVera Troitskaya
- Sergey KulikovSKSergey Kulikov
- Elena ParovichnikovaEPElena Parovichnikova
Open Access
- 21 December 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (1) , 21
Abstract
Measurable residual disease (MRD) is a well-known independent prognostic factor in acute leukemias, and multicolor flow cytometry (MFC) is widely used to detect MRD. MFC is able not only to enumerate MRD accurately but also to describe an antigen expression profile of residual blast cells. However, the relationship between MRD immunophenotype and patient survival probability has not yet been studied. We determined the prognostic impact of MRD immunophenotype in adults with B-cell acute lymphoblastic leukemia (B-ALL). In a multicenter study RALL-2016 (NCT03462095), 267 patients were enrolled from 2016 to 2022. MRD was assessed at the end of induction (day 70) in 94 patients with B-ALL by six- or 10-color flow cytometry in the bone marrow specimens. The 4 year relapse-free survival (RFS) was lower in MRD-positive B-ALL patients [37% vs. 78% (p < 0.0001)]. The absence of CD10, positive expression of CD38, and high expression of CD58 on MRD cells worsened the 4 year RFS [19% vs. 51% (p = 0.004), 0% vs. 51% (p < 0.0001), and 21% vs. 40% (p = 0.02), respectively]. The MRD immunophenotype is associated with RFS and could be an additional prognostic factor for B-ALL patients.Keywords
This publication has 47 references indexed in Scilit:
- Modulation of antigen expression in B‐cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug‐induced regulatory phenomenon. Results of the AIEOP‐BFM‐ALL‐FLOW‐MRD‐Study GroupCytometry Part B: Clinical Cytometry, 2010
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2009
- Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasibleCytometry Part B: Clinical Cytometry, 2008
- Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemiaLeukemia, 2008
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL)Blood, 2005
- CD58 Expression Decreases as Nonmalignant B Cells Mature in Bone Marrow and Is Frequently Overexpressed in Adult and Pediatric Precursor B-Cell Acute Lymphoblastic LeukemiaAmerican Journal of Clinical Pathology, 2005
- TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapseLeukemia, 2004
- Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10−/CD24−/CD65s+/CD15+ B-cell phenotypeLeukemia, 2003
- Different expression of adhesion molecules on CD34+ cells in AML and B‐lineage ALL and their normal bone marrow counterpartsEuropean Journal of Haematology, 1999